FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceuticals. The 1st object is a pharmaceutical composition containing particles containing at least 95 wt % taxane selected from paclitaxel and docetaxel, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, while these paclitaxel particles have a specific surface area (SSA), measured by the Brunauer-Emmet-Teller (BET) method, from 18 m2/g to 40 m2/g and an average volume density from 0.050 g/cm3 to 0.12 g/cm3 and these docetaxel particles have an SSA measured by the BET method of 18 m2/g to 50 m2/g and an average volume density of 0.050. The 3rd object is a method for producing particles containing at least 95 wt % taxane selected from paclitaxel and docetaxel.
EFFECT: increased solubility of paclitaxel or docetaxel particles with increased specific surface area and reduced volume density.
19 cl, 10 dwg, 5 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING SOLID TUMORS | 2017 |
|
RU2737934C2 |
METHODS FOR TREATMENT OF LUNG DISORDERS | 2018 |
|
RU2773750C2 |
TREATMENT OF CANCER BY COMBINATION OF PLINABULIN AND TAXANE | 2013 |
|
RU2662298C2 |
CANCER THERAPY BY COMBINATION OF TAXANES AND 13-DEOXYANTRACYCLINES | 2007 |
|
RU2421224C2 |
METHOD AND COMPOSITION FOR PERORAL INTAKE OF TAXANES BY A PATIENT | 1998 |
|
RU2205005C2 |
ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING TAXANES AND METHODS FOR TREATMENT USING THEREOF | 1999 |
|
RU2236226C2 |
TREATING THREE RECEPTOR NEGATIVE BREAST CANCER | 2007 |
|
RU2448697C2 |
STABLE EMULSION FOR PARENTERAL INTRODUCTION OF BADLY SOLUBLE IN WATER COMPOUNDS, WHICH HAVE ANTI-TUMOR ACTIVITY, AND METHOD OF ITS OBTAINING | 2007 |
|
RU2370261C2 |
METHODS FOR COMBINATION THERAPY OF PROLIFERATIVE DISEASES | 2011 |
|
RU2577278C2 |
COMBINATION TREATMENT | 2014 |
|
RU2666999C2 |
Authors
Dates
2021-06-22—Published
2016-06-06—Filed